论文部分内容阅读
大剂量联合化疗虽然使急性白血病(AL)的缓解率及缓解期有了明显的改善,但绝大多数病人在3年内终于复发。异基因骨髓移植(BMT)很有希望成为根治AL的方法,但受到选择适合供者来源的限制。在欧洲,约30%的AL病人有HLA相配的同胞供者,在美国约23～40%,在我国不足1/4,随着计划生育工作进一步落实,将来绝大多数病人很难找到HLA相配同胞供者,即使有幸能接受HLA相配同胞供者的BMT,其伴
Although large doses of combination chemotherapy in acute leukemia (AL) response rate and remission have been significantly improved, but the vast majority of patients finally relapsed within 3 years. Allogeneic bone marrow transplantation (BMT) is promising as a cure for AL, but is limited in its choice of donor source. In Europe, about 30% of AL patients have HLA-matched sibling donors, about 23-40% in the United States and less than 1/4 in our country. With the further implementation of family planning work, it is difficult for most patients to find HLA matching in the future Fellow compatriots, even if fortunate enough to accept HLA matched sibling donor BMT, its partner